Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway
Authors:
Open Access
- 22 March 2012
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 106 (9) , 1571-1578
Abstract
Background: Methods: Results: Conclusions:Keywords
This publication has 29 references indexed in Scilit:
- Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyBMJ, 2008
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 VaccinationJNCI: Journal of the National Cancer Institute, 2008
- 2006 consensus guidelines for the management of women with abnormal cervical cancer screening testsAmerican Journal of Obstetrics and Gynecology, 2007
- Chapter 9: Clinical applications of HPV testing: A summary of meta-analysesVaccine, 2006
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and ItalyJNCI: Journal of the National Cancer Institute, 2005
- Trends in Cervical Squamous Cell Carcinoma Incidence in 13 European Countries: Changing Risk and the Effects of ScreeningCancer Epidemiology, Biomarkers & Prevention, 2005
- The cervical cancer epidemic that screening has prevented in the UKThe Lancet, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003